Greenbrook TMS, a Bristol Capital client, announced its second quarter 2022 operational and financial results. Some operational and financial highlights: Revenue for Q2 2022 increased by 4% to a record high of $14.2 million. Quarterly treatment volumes increased by 7% to a record high of 62,038 and consultations performed increased by 22. Greenbrook continued the roll-out of Spravato® nasal spray to 25 TMS Centers across the United States, building on the long-term business plan of utilizing the centres as platforms for innovative treatments to patients suffering from mental health disorders such as Major Depressive Disorder.

Read the full press release here: Greenbrook TMS Reports Second Quarter Operational and Financial Results